Steris plc (STE)

Name: Steris plc (STE): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Steris plc (STE) reported revenue of $1.5 billion for Q1 FY2027, the quarter ended 30 June 2026, up 7.3% on the same quarter a year earlier. Net income was $200 million, up 12.8% on the year. The figures are the company's own, from the 10-Q it filed with the SEC on 7 August 2026.

Revenue$1.5 billionup 7.3%

Net income$200 millionup 12.8%

Diluted EPSn/a

QuarterQ1 FY2027ended 30 June 2026

Ratios

From the filings

ROE11.2%

ROCE12.5%

Operating margin18.9%

Net margin13.3%

FCF margin15.3%

Interest cover18.84

Debt to equity0.26

Cash conversion1.60

Share count, 1 year-1.0%

Sales CAGR, 3 years9.4%

Profit CAGR, 3 years94.1%

EPS, TTMn/a

At the close of 21 September 2026

Price$206.97

Market cap$20.2 billion

Stock P/E25.29

Price to book2.80

EV / EBITDA13.23

Dividend yield1.2%

Market cap / sales3.34

52-week high$268.65

52-week low$199.40

Price, 1 year-16.8%

Price CAGR, 3 years-2.6%

Price CAGR, 5 years-0.8%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on the total debt Steris plc states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on STE

Filings	17 in twelve months: 8 current reports (8-K), about 4 results of operations; 3 officer or director change; 1 shareholder vote; 1 exit or disposal costs; 1 regulation fd disclosure
Planned insider sales	11 Form 144 notices in twelve months, $10.8 million; latest 18 August 2026
Options tape	put/call 1.14 by open interest on 23 September 2026; the straddle prices a 5.1% move to 16 October 2026
Holders	8 of the followed funds hold it; largest Geode Capital Management; 5 Schedule 13D or 13G filings in twelve months
Insider trading	13 sales and 0 purchases on Form 4 in twelve months
Congress	12 House trades disclosed in six months
Short interest	2.4 million shares short, 4.08 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026	Q4 FY2026 *	Q1 FY2027
Revenue	1,342	1,396	1,419	1,280	1,329	1,371	1,481	1,391	1,460	1,496	1,588	1,493
Cost of revenue	749	793	836	707	750	760	n/a	763	814	841	891	809
Gross profit	594	603	583	572	579	610	641	628	646	656	697	684
Gross margin	44%	43%	41%	45%	44%	45%	43%	45%	44%	44%	44%	46%
R&D	27.0	25.9	25.2	25.6	27.0	27.4	27.7	26.4	28.2	29.5	28.8	28.6
SG&A	381	361	152	336	329	335	334	354	350	352	352	370
Operating income	186	216	245	186	220	245	216	246	266	273	317	286
Operating margin	14%	15%	17%	15%	17%	18%	15%	18%	18%	18%	20%	19%
Interest expense	36.9	38.9	36.1	30.4	19.7	19.1	17.1	15.9	14.9	14.9	15.0	15.8
Pre-tax income	150	179	191	175	195	229	197	232	253	258	304	274
Tax rate	23%	21%	20%	20%	22%	24%	26%	23%	24%	25%	28%	27%
Net income	115	141	-1.4	145	150	174	146	177	192	193	220	200
Net margin	9%	10%	-0%	11%	11%	13%	10%	13%	13%	13%	14%	13%
Diluted EPS	$1.16	$1.42	-$0.01	$1.46	$1.51	$1.75	$1.48	$1.79	$1.94	$1.96	$2.24	n/a
Operating cash flow	146	291	255	304	251	333	261	420	288	298	335	367
Capital expenditure	83.3	119	91.5	108	102	89.2	70.9	93.6	86.5	98.7	90.2	87.5
Free cash flow	62.8	172	163	196	149	244	190	326	201	200	245	280
Buybacks	0.5	2.2	0.3	64.2	46.4	100	0.3	10.6	100	50.1	74.3	116
Dividends paid	51.4	51.4	51.4	51.4	56.2	56.2	56.0	56.2	61.9	61.9	61.8	61.4
Shares outstanding	99m	99m	99m	99m	99m	98m	98m	98m	98m	98m	98m	98m
Filing	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 10 fiscal years and the trailing twelve months

	FY2017	FY2018	FY2019	FY2020 †	FY2021	FY2022 †	FY2023 †	FY2024 †	FY2025	FY2026	TTM
Revenue	2,613	2,620	2,782	3,031	3,108	4,223	4,536	5,139	5,460	5,936	6,038
Cost of revenue	1,587	1,527	1,607	1,711	1,764	2,340	2,556	2,921	3,057	3,309	3,355
Gross profit	1,026	1,093	1,175	1,320	1,343	1,883	1,981	2,218	2,403	2,626	2,683
Gross margin	39.3%	41.7%	42.2%	43.5%	43.2%	44.6%	43.7%	43.2%	44.0%	44.2%	44.4%
Research and development	59.4	60.8	63.0	65.5	66.3	86.7	98.5	104	108	113	115
Selling, general and administrative	682	632	670	717	731	1,318	1,091	1,252	1,334	1,408	1,424
Operating income	226	400	411	537	548	478	791	836	867	1,102	1,142
Operating margin	8.7%	15.3%	14.8%	17.7%	17.6%	11.3%	17.4%	16.3%	15.9%	18.6%	18.9%
Interest expense	44.5	50.6	45.0	40.3	37.2	89.6	108	144	86.3	60.7	60.6
Pre-tax income	185	355	369	499	518	367	680	703	796	1,047	1,089
Income tax	74.0	63.4	64.4	90.9	121	82.3	124	150	185	262	281
Effective tax rate	40.1%	17.8%	17.4%	18.2%	23.3%	22.4%	18.2%	21.3%	23.2%	25.0%	25.8%
Net income	110	291	304	408	397	244	107	378	615	782	805
Net margin	4.2%	11.1%	10.9%	13.4%	12.8%	5.8%	2.4%	7.4%	11.3%	13.2%	13.3%
Diluted EPS	$1.28	$3.39	$3.56	$4.76	$4.63	$2.48	$1.07	$3.81	$6.20	$7.93	n/a
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2017	FY2018	FY2019	FY2020 †	FY2021	FY2022 †	FY2023 †	FY2024 †	FY2025	FY2026	TTM
Operating cash flow	424	458	540	591	690	685	757	973	1,148	1,341	1,288
Capital expenditure	173	165	190	215	239	288	362	360	370	369	363
Free cash flow	251	292	350	376	450	397	395	613	778	972	926
Free cash flow margin	9.6%	11.2%	12.6%	12.4%	14.5%	9.4%	8.7%	11.9%	14.3%	16.4%	15.3%
Depreciation and amortisation	188	178	226	197	219	553	553	565	476	486	491
Share-based compensation	18.8	22.2	24.0	23.8	26.0	57.7	39.0	56.5	57.4	61.7	62.6
Buybacks	97.5	65.5	81.5	51.2	14.6	55.8	309	11.8	211	236	340
Dividends paid	93.2	103	113	123	134	163	183	201	220	242	247
Dividend per share	$1.09	$1.21	$1.33	$1.45	$1.57	$1.69	$1.84	$2.03	$2.23	$2.46	n/a
Diluted shares, weighted	86m	86m	85m	86m	86m	98m	100m	99m	99m	99m	98m
Shares outstanding at period end	n/a	85m	85m	85m	85m	100m	99m	99m	98m	98m	98m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2017	FY2018	FY2019	FY2020 †	FY2021	FY2022 †	FY2023 †	FY2024 †	FY2025	FY2026	TTM
Total assets	n/a	5,200	5,073	5,441	6,574	11,424	10,822	11,064	10,147	10,737	10,736
Cash and equivalents	283	202	221	320	221	348	208	207	172	440	482
Receivables	n/a	528	565	586	609	799	865	1,008	1,044	1,093	1,013
Inventory	n/a	206	208	264	315	575	604	675	581	632	712
Goodwill	2,231	2,434	2,323	2,356	3,026	3,939	3,879	4,071	4,096	4,195	4,189
Total debt, as filed	n/a	n/a	n/a	1,151	1,651	3,088	3,079	3,206	2,044	1,932	1,894
Long-term debt	n/a	1,316	1,183	1,151	1,651	2,945	3,019	3,120	1,919	1,813	1,650
Borrowings, as the company tags them	n/a	n/a	n/a	878	860	759	n/a	n/a	n/a	n/a	n/a
Operating lease liabilities	n/a	n/a	n/a	n/a	130	155	140	146	125	120	n/a
Shareholders' equity	2,810	3,206	3,178	3,405	3,881	6,532	6,077	6,302	6,603	7,184	7,207
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	n/a	13.8%	9.4%	8.4%
Profit growth, compounded	n/a	14.5%	94.1%	24.5%
Return on equity, average	7.6%	6.3%	8.7%	10.9%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Orthopedic, Prosthetic & Surgical Appliances & Supplies

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Intuitive Surgical Inc. ISRG	$142.1 billion	46.11	17.3%	31.3%	20.7%	n/a	n/a
Edwards Lifesciences Corp. EW	$50.9 billion	50.77	9.5%	22.3%	14.6%	0.06	n/a
Steris plc STE	$20.2 billion	25.29	11.2%	18.9%	8.4%	0.26	1.2%
Zimmer Biomet Holdings, Inc. ZBH	$18.0 billion	22.89	6.4%	14.2%	8.6%	0.50	1.0%
Align Technology Inc. ALGN	$10.5 billion	25.59	9.8%	13.2%	4.4%	n/a	n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	7 August 2026	EDGAR
10-K	31 March 2026	29 May 2026	EDGAR
10-Q	31 December 2025	6 February 2026	EDGAR
10-Q	30 September 2025	6 November 2025	EDGAR
10-Q	30 June 2025	7 August 2025	EDGAR
10-K	31 March 2025	29 May 2025	EDGAR
10-Q	31 December 2024	7 February 2025	EDGAR
10-Q	30 September 2024	7 November 2024	EDGAR
10-Q	30 June 2024	8 August 2024	EDGAR
10-K	31 March 2024	29 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install